Olmesartán/Amlodipino Viatris (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine Viatris, is an angiotensin II receptor blocker presented as a tablet for oral use. It lowers blood pressure in adults with hypertension, often combined with amlodipine, a calcium‑channel blocker, to improve control. The combination is indicated for patients whose blood pressure is not adequately controlled with monotherapy.

GNH USA supplies Olmesartan/Amlodipine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine is a combination antihypertensive that targets the renin‑angiotensin system and calcium channels to manage high blood pressure.

Essential hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. High‑risk hypertension: improves control in patients with additional cardiovascular risk factors. Resistant hypertension: offers an oral dual‑action option for patients needing multiple agents.

The combination may cause a range of adverse reactions, from frequent to rare.

Common Side Effects: - Dizziness: light‑headed feeling, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of the ankles or feet. - Flushing: transient warmth and redness of the skin.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

When using Olmesartan/Amlodipine, certain safety measures should be observed.

Blood pressure monitoring: check regularly to avoid hypotension. Pregnancy: avoid use because of fetal risk. Renal impairment: adjust dose and monitor function. Electrolyte balance: watch for hyperkalemia when combined with potassium‑sparing agents. Concomitant CYP3A4 inhibitors: may increase amlodipine levels; monitor. Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan/Amlodipine can interact with several medicines; awareness helps maintain efficacy and safety.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can cause renal impairment and hyperkalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase amlodipine exposure, raising risk of hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): may raise potassium levels when used with olmesartan.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, diuretics): additive blood‑pressure lowering effect. - NSAIDs: may reduce antihypertensive efficacy of olmesartan. - Lithium: may increase lithium levels; monitor serum concentration.